tradingkey.logo

Certara Inc

CERT
View Detailed Chart

11.480USD

-0.310-2.63%
Close 09/19, 16:00ETQuotes delayed by 15 min
1.84BMarket Cap
231.03P/E TTM

Certara Inc

11.480

-0.310-2.63%
Intraday
1m
30m
1h
D
W
M
D

Today

-2.63%

5 Days

+1.77%

1 Month

+4.17%

6 Months

+7.39%

Year to Date

+7.79%

1 Year

+1.50%

View Detailed Chart

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered undervalued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a weak stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking
79 / 470
Overall Ranking
143 / 4720
Industry
Software & IT Services

Support & Resistance

No Data

Score Analysis

Current score
Previous score

Analyst Rating

Based on 11 analysts
Buy
Current Rating
14.444
Target Price
+22.51%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks
Certara, Inc. is engaged in model-informed drug development. The Company accelerates medicine using biosimulation software, technology and services to transform traditional drug discovery and development. It delivers software products and technology-driven services to customers to efficiently carry out and realize the full benefits of biosimulation in drug discovery, preclinical and clinical research, regulatory submissions and market access. Its regulatory science and market access software and services are underpinned by technologies such as regulatory submissions software, natural language processing and Bayesian analytics. It also develops scientific informatics software products used by the life sciences industry for in-silico research. It develops advanced modeling and biosimulation solutions used to predict the pharmacokinetic and pharmacodynamic properties. Its clients include 2,400 biopharmaceutical companies, academic institutions and regulatory agencies across 66 countries.
Overvalued
The company’s latest PE is 229.78, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 167.47M shares, decreasing 14.76% quarter-over-quarter.
Held by Wasatch Global Investors
Star Investor Wasatch Global Investors holds 13.53M shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of 0.19.

News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Company

Certara, Inc. is engaged in model-informed drug development. The Company accelerates medicine using biosimulation software, technology and services to transform traditional drug discovery and development. It delivers software products and technology-driven services to customers to efficiently carry out and realize the full benefits of biosimulation in drug discovery, preclinical and clinical research, regulatory submissions and market access. Its regulatory science and market access software and services are underpinned by technologies such as regulatory submissions software, natural language processing and Bayesian analytics. It also develops scientific informatics software products used by the life sciences industry for in-silico research. It develops advanced modeling and biosimulation solutions used to predict the pharmacokinetic and pharmacodynamic properties. Its clients include 2,400 biopharmaceutical companies, academic institutions and regulatory agencies across 66 countries.
Ticker SymbolCERT
CompanyCertara Inc
CEODr. William F. (Bill) Feehery, Ph.D.
Websitehttps://www.certara.com/
KeyAI